LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway

Xu,Ruyue; Zhang,Yinci; Li,Amin; Ma,Yongfang; Cai,Wenpeng; Song,Li; Xie,Yinghai; Zhou,Shuping; Cao,Weiya; Tang,Xiaolong

doi:10.3892/mmr.2021.12147

July-2021 Volume 24 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2021 Volume 24 Issue 1

Full Size Image

Article Open Access

LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway

Authors:
- Ruyue Xu
- Yinci Zhang
- Amin Li
- Yongfang Ma
- Wenpeng Cai
- Li Song
- Yinghai Xie
- Shuping Zhou
- Weiya Cao
- Xiaolong Tang
View Affiliations / Copyright

Affiliations: Medical School, Anhui University of Science and Technology, Huainan, Anhui 232001, P.R. China, Institute of Environmentally Friendly Materials and Occupational Health, Anhui University of Science and Technology, Wuhu, Anhui 241000, P.R. China

Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 508
|
Published online on: May 11, 2021

https://doi.org/10.3892/mmr.2021.12147
Expand metrics +

Abstract

Liver cancer remains one of the leading causes of cancer deaths worldwide. The therapeutic effect of oxaliplatin on liver cancer is often limited by acquired resistance of the cancer cells. Abnormal activation of the PI3K/AKT pathway plays an important role in the acquired resistance of oxaliplatin. The present study investigated the effects of the PI3K inhibitor LY‑294002 and AKT inhibitor MK2206 on the chemosensitivity of oxaliplatin‑resistant liver cancer cells and the molecular mechanism involved. An oxaliplatin‑resistant liver cancer cell line HepG2^R was developed. MTT assay, clone formation experiments, flow cytometry and Annexin V‑FITC/PI staining were used to determine the proliferation, cycle and apoptosis of HepG2^R cells when oxaliplatin was combined with LY‑294002 or MK2206 treatment. The effects of LY‑294002 and MK‑2206 on the abnormal activation of PI3K/AKT pathway and hypoxia inducible factor (HIF)‑1α protein level in HepG2^R cells were detected using western blotting. The results indicated that the PI3K/AKT pathway is stably activated in HepG2^R cells. Compared with the AKT inhibitor MK2206, the PI3K inhibitor LY‑294002 more effectively downregulated the phosphorylation levels of p85, p110α, p110β, p110γ and AKT in the PI3K/AKT pathway in HepG2^R cells, and more effectively inhibited the proliferation of the cells. LY‑294002 enhanced the chemotherapy sensitivity of HepG2R cells to oxaliplatin by inducing G₀/G₁ phase arrest and increasing the proportion of apoptotic cells. In addition, LY‑294002 reduced the level of HIF‑1α, which is highly expressed in HepG2^R cells. It was concluded that LY‑294002 enhanced the chemosensitivity of liver cancer cells to oxaliplatin by inhibiting the PI3K/AKT signaling pathway, which may be related to the inhibition of HIF‑1α expression. These findings may have clinical significance for the treatment of oxaliplatin‑resistant liver cancer.

View Figures

View References

1	Feng RM, Zong YN, Cao SM and Xu RH: Current cancer situation in China: Good or bad news from the 2018 Global cancer statistics? Cancer Commun (Lond). 39:222019. View Article : Google Scholar : PubMed/NCBI
2	Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, Martinez-Tyson D, Jemal A and Siegel RL: Cancer statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 68:425–445. 2018. View Article : Google Scholar : PubMed/NCBI
3	Li A, Zhang R, Zhang Y, Liu X, Wang R, Liu J, Liu X, Xie Y, Cao W, Xu R, et al: BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway. Am J Transl Res. 11:5573–5585. 2019.PubMed/NCBI
4	Smith DK and Murphy BA: Lower levels of education and household income mediate lower dental care utilization among survivors of early life cancers. Prev Med Rep. 14:1008682019. View Article : Google Scholar : PubMed/NCBI
5	Liu X, Xie C, Li A, Zhang Y, Liu X, Zhou S, Shen J, Huo Z, Cao W, Ma Y, et al: BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway. Am J Transl Res. 11:7255–7271. 2019.PubMed/NCBI
6	Yang Y, Yao JH, Du QY, Zhou YC, Yao TJ, Wu Q, Liu J and Ou YR: Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT. Cancer Manag Res. 11:5133–5146. 2019. View Article : Google Scholar : PubMed/NCBI
7	Ye JZ, Yan SM, Yuan CL, Wu HN, Zhang JY, Liu ZH, Li YQ, Luo XL, Lin Y and Liang R: GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells. J Cancer. 9:415–423. 2018. View Article : Google Scholar : PubMed/NCBI
8	Zhu YJ, Zheng B, Wang HY and Chen L: New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
9	Zhang Y, Liu X, Zhang J, Xu Y, Shao J, Hu Y, Shu P and Cheng H: Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway. Aging (Albany NY). 12:5640–5650. 2020. View Article : Google Scholar : PubMed/NCBI
10	Kang HG, Wang BZ, Zhang J, Liu MR and Li YX: Combination of temsirolimus and Adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 41:197–203. 2017. View Article : Google Scholar : PubMed/NCBI
11	Sun X, Su Y, He Y, Zhang J, Liu W, Zhang H, Hou Z, Liu J and Li J: New strategy for in vitro activation of primordial follicles with mTOR and PI3K stimulators. Cell Cycle. 14:721–731. 2015. View Article : Google Scholar : PubMed/NCBI
12	Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell. 170:605–635. 2017. View Article : Google Scholar : PubMed/NCBI
13	Aoki M and Fujishita T: Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189. 2017.PubMed/NCBI
14	Grosbois J and Demeestere I: Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation. Hum Reprod. 33:1705–1714. 2018. View Article : Google Scholar : PubMed/NCBI
15	Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ and Li Y: Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 96:507–517. 2015. View Article : Google Scholar : PubMed/NCBI
16	Brown JS and Banerji U: Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 172:101–115. 2017. View Article : Google Scholar : PubMed/NCBI
17	Mehal W: NASH and HCC are driven by different signaling pathways with a common regulator. Cell Metab. 29:3–4. 2019. View Article : Google Scholar : PubMed/NCBI
18	Lee JH, Lee HJ, Sim DY, Jung JH, Kim KR and Kim SH: Apoptotic effect of lambertianic acid through AMPK/FOXM1 signaling in MDA-MB231 breast cancer cells. Phytother Res. 32:1755–1763. 2018. View Article : Google Scholar : PubMed/NCBI
19	Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 21:3995–4004. 2001. View Article : Google Scholar : PubMed/NCBI
20	Qu D, Weygant N, Yao J, Chandrakesan P, Berry WL, May R, Pitts K, Husain S, Lightfoot S, Li M, et al: Overexpression of DCLK1-AL increases tumor cell invasion, drug resistance, and KRAS activation and can be targeted to inhibit tumorigenesis in pancreatic cancer. J Oncol. 2019:64029252019. View Article : Google Scholar : PubMed/NCBI
21	Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S and Neri LM: The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget. 4:1496–1506. 2013. View Article : Google Scholar : PubMed/NCBI
22	Yu X, Liu J, Qiu H, Hao H, Zhu J and Peng S: Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer. Bosn J Basic Med Sci. 21:198–207. 2021.PubMed/NCBI
23	Li YL, Weng HC, Hsu JL, Lin SW, Guh JH and Hsu LC: The combination of MK-2206 and WZB117 exerts a synergistic cytotoxic effect against breast cancer cells. Front Pharmacol. 10:13112019. View Article : Google Scholar : PubMed/NCBI
24	Zhu Y, Zhong Y, Long X, Zhu Z, Zhou Y, Ye H, Zeng X and Zheng X: Deoxyshikonin isolated from Arnebia euchroma inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway. Pharm Biol. 57:412–423. 2019. View Article : Google Scholar : PubMed/NCBI
25	Wang X, Wang X, Xu Y, Yan M, Li W, Chen J and Chen T: Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K/AKT signalling pathway modulation. Cancer Cell Int. 20:912020. View Article : Google Scholar : PubMed/NCBI
26	Jiao M and Nan KJ: Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol. 40:461–468. 2012.PubMed/NCBI
27	Ling S, Li J, Shan Q, Dai H, Lu D, Wen X, Song P, Xie H, Zhou L, Liu J, et al: USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol. 11:682–695. 2017. View Article : Google Scholar : PubMed/NCBI
28	Ma J, Xie SL, Geng YJ, Jin S, Wang GY and Lv GY: In vitro regulation of hepatocellular carcinoma cell viability, apoptosis, invasion, and AEG-1 expression by LY294002. Clin Res Hepatol Gastroenterol. 38:73–80. 2014. View Article : Google Scholar : PubMed/NCBI
29	Elefantova K, Lakatos B, Kubickova J, Sulova Z and Breier A: Detection of the mitochondrial membrane potential by the cationic Dye JC-1 in L1210 cells with massive overexpression of the plasma membrane ABCB1 drug transporter. Int J Mol Sci. 19:19852018. View Article : Google Scholar : PubMed/NCBI
30	Tang X, Li A, Xie C, Zhang Y, Liu X, Xie Y, Wu B, Zhou S, Huang X, Ma Y, et al: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway. Nanoscale Res Lett. 15:632020. View Article : Google Scholar : PubMed/NCBI
31	Devanabanda B and Kasi A: Oxaliplatin. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright© 2020, StatPearls Publishing LLC; 2020
32	Tang X, Chen L, Li A, Cai S, Zhang Y, Liu X, Jiang Z, Liu X, Liang Y and Ma D: Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv. 25:1484–1494. 2018. View Article : Google Scholar : PubMed/NCBI
33	Shen JH, Chen PH, Liu HD, Huang DA, Li MM and Guo K: HSF1/AMPKα2 mediated alteration of metabolic phenotypes confers increased oxaliplatin resistance in HCC cells. Am J Cancer Res. 9:2349–2363. 2019.PubMed/NCBI
34	Liao X, Song G, Xu Z, Bu Y, Chang F, Jia F, Xiao X, Ren X, Zhang M and Jia Q: Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma. BMC Cancer. 20:312020. View Article : Google Scholar : PubMed/NCBI
35	He J, Ma J, Ren B and Liu A: Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway. Semin Arthritis Rheum. 50:314–320. 2020. View Article : Google Scholar : PubMed/NCBI
36	Mammana S, Bramanti P, Mazzon E, Cavalli E, Basile MS, Fagone P, Petralia MC, McCubrey JA, Nicoletti F and Mangano K: Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. Oncotarget. 9:8263–8277. 2018. View Article : Google Scholar : PubMed/NCBI
37	Nicoletti F, Fagone P, Meroni P, McCubrey J and Bendtzen K: mTOR as a multifunctional therapeutic target in HIV infection. Drug Discov Today. 16:715–721. 2011. View Article : Google Scholar : PubMed/NCBI
38	Fagone P, Ciurleo R, Lombardo SD, Iacobello C, Palermo CI, Shoenfeld Y, Bendtzen K, Bramanti P and Nicoletti F: Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmun Rev. 19:1025712020. View Article : Google Scholar : PubMed/NCBI
39	Gong C, Ai J, Fan Y, Gao J, Liu W, Feng Q, Liao W and Wu L: NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling. Onco Targets Ther. 12:8537–8552. 2019. View Article : Google Scholar : PubMed/NCBI
40	Xie Y and Zhong DW: AEG-1 is associated with hypoxia-induced hepatocellular carcinoma chemoresistance via regulating PI3K/AKT/HIF-1alpha/MDR-1 pathway. EXCLI J. 15:745–757. 2016.PubMed/NCBI
41	Li XZ, Sun YL, Cao LQ and Li MJ: Oxaliplatin-rapamycin combination was superior to mono-drug in treatment of hepatocellular carcinoma both in vitro and in vivo. Neoplasma. 63:880–887. 2016. View Article : Google Scholar : PubMed/NCBI
42	Liao B, Zhang Y, Sun Q and Jiang P: Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells. Cancer Med. 7:196–207. 2018. View Article : Google Scholar : PubMed/NCBI
43	Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, Nan K, Yao Y and Tian T: MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 108:620–631. 2017. View Article : Google Scholar : PubMed/NCBI
44	Zhang Y, Xie C, Li A, Liu X, Xing Y, Shen J, Huo Z, Zhou S, Liu X, Xie Y, et al: PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway. Am J Transl Res. 11:5134–5149. 2019.PubMed/NCBI
45	Wang Y, Nie H, Zhao X, Qin Y and Gong X: Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer. 16:7422016. View Article : Google Scholar : PubMed/NCBI
46	Li TT, Zhu D, Mou T, Guo Z, Pu JL, Chen QS, Wei XF and Wu ZJ: IL-37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway. Mol Immunol. 87:132–140. 2017. View Article : Google Scholar : PubMed/NCBI
47	Zhu F, Jiang D, Zhang M and Zhao B: 2,4-Dihydroxy- 3′-methoxy-4′-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway. Pharm Biol. 57:641–648. 2019. View Article : Google Scholar : PubMed/NCBI
48	Fang X, Yang D, Luo H, Wu S, Dong W, Xiao J, Yuan S, Ni A, Zhang KJ, Liu XY and Chu L: SNORD126 promotes HCC and CRC cell growth by activating the PI3K-AKT pathway through FGFR2. J Mol Cell Biol. 9:243–255. 2017.PubMed/NCBI
49	Zhou M, Zhang Q, Zhao J, Liao M, Wen S and Yang M: Phosphorylation of Bcl-2 plays an important role in glycochenodeoxycholate-induced survival and chemoresistance in HCC. Oncol Rep. 38:1742–1750. 2017. View Article : Google Scholar : PubMed/NCBI
50	Pan W, Li W, Zhao J, Huang Z, Zhao J, Chen S, Wang C, Xue Y, Huang F, Fang Q, et al: lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway. Mol Oncol. 13:2246–2258. 2019. View Article : Google Scholar : PubMed/NCBI
51	Jiang S, Wang Q, Feng M, Li J, Guan Z, An D, Dong M, Peng Y, Kuerban K and Ye L: C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. Appl Microbiol Biotechnol. 101:1535–1546. 2017. View Article : Google Scholar : PubMed/NCBI
52	Sui Y, Zheng X and Zhao D: Rab31 promoted hepatocellular carcinoma (HCC) progression via inhibition of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway. Tumour Biol. 36:8661–8670. 2015. View Article : Google Scholar : PubMed/NCBI
53	Mendez-Blanco C, Fondevila F, Garcia-Palomo A, Gonzalez-Gallego J and Mauriz JL: Sorafenib resistance in hepatocarcinoma: Role of hypoxia-inducible factors. Exp Mol Med. 50:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
54	Gong J, Zhou S and Yang S: Vanillic Acid Suppresses HIF-1α expression via inhibition of mTOR/p70S6K/4E-BP1 and Raf/MEK/ERK pathways in human colon cancer HCT116 cells. Int J Mol Sci. 20:4652019. View Article : Google Scholar : PubMed/NCBI
55	Xu LF, Ni JY, Sun HL, Chen YT and Wu YD: Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells. World J Gastroenterol. 19:1749–1759. 2013. View Article : Google Scholar : PubMed/NCBI
56	Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, et al: Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway. Oncogene. 35:2506–2517. 2016. View Article : Google Scholar : PubMed/NCBI
57	Ferrin G, Guerrero M, Amado V, Rodriguez-Peralvarez M and De la Mata M: Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci. 21:12662020. View Article : Google Scholar : PubMed/NCBI
58	Duan Y, Haybaeck J and Yang Z: Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: Rationale and progress. Cancers (Basel). 12:29722020. View Article : Google Scholar : PubMed/NCBI
59	Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL and McCubrey JA: The therapeutic potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol. 82:1189–1212. 2016. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles